[Statin-induced dysphagia].
A 68-year-old man was referred with progressive dysphagia. During the course, the patient developed muscle fatigue and additional signs of myopathy such as high levels of creatine kinase. The dysphagia was a late-onset side-effect to the treatment with lipid-lowering drugs. Cessation of treatment gives quick remission of symptoms and normalization of creatine kinase. As an increasing number of patients are being treated with lipid-lowering drugs, it is important to recall that myopathy is a dangerous side-effect which may have either quick or delayed onset, and that dysphagia can be the initial symptom.
Edholm
Bjarke
B
Øre-naese-halskirurgisk Afdeling, Slagelse Sygehus, DK-5000 Odense C, Denmark. bjarkeedholm@hotmail.com
D000924:Anticholesteremic Agents / Q000009:adverse effects*; D000069059:Atorvastatin; D003680:Deglutition Disorders / Q000139:chemically induced*; D006538:Heptanoic Acids / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced; D011758:Pyrroles / Q000009:adverse effects*
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin